| Progressive immune dysfunction with advancing disease stage in renal cell carcinoma DA Braun, K Street, KP Burke, DL Cookmeyer, T Denize, CB Pedersen, ... Cancer Cell 39 (5), 632-648. e8, 2021 | 264 | 2021 |
| Checkpoint inhibitor immunotherapy in kidney cancer W Xu, MB Atkins, DF McDermott Nature Reviews Urology 17 (3), 137-150, 2020 | 197 | 2020 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study W Xu, SI Goldberg, M Shubina, A Turchin bmj 350, 2015 | 162 | 2015 |
| Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study W Xu, SI Goldberg, M Shubina, A Turchin bmj 350, 2015 | 162 | 2015 |
| Mitotic cell death by chromosome fragmentation JB Stevens, G Liu, SW Bremer, KJ Ye, W Xu, J Xu, Y Sun, GS Wu, ... Cancer research 67 (16), 7686-7694, 2007 | 119 | 2007 |
| Compensatory mutations restore fitness during the evolution of dihydrofolate reductase KM Brown, MS Costanzo, W Xu, S Roy, ER Lozovsky, DL Hartl Molecular biology and evolution 27 (12), 2682-2690, 2010 | 116 | 2010 |
| Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors AH Nassar, E Adib, S Abou Alaiwi, T El Zarif, S Groha, EW Akl, PV Nuzzo, ... Cancer Cell 40 (10), 1161-1172. e5, 2022 | 55 | 2022 |
| Natural language processing to ascertain cancer outcomes from medical oncologist notes KL Kehl, W Xu, E Lepisto, H Elmarakeby, MJ Hassett, EM Van Allen, ... JCO Clinical Cancer Informatics 4, 680-690, 2020 | 51 | 2020 |
| Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma L Hirsch, NM Chanza, S Farah, W Xie, R Flippot, DA Braun, N Rathi, ... JAMA oncology 7 (12), 1815-1823, 2021 | 49 | 2021 |
| Germline variants associated with toxicity to immune checkpoint blockade S Groha, SA Alaiwi, W Xu, V Naranbhai, AH Nassar, Z Bakouny, T El Zarif, ... Nature medicine 28 (12), 2584-2591, 2022 | 48 | 2022 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 38 | 2021 |
| Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset KL Kehl, W Xu, A Gusev, Z Bakouny, TK Choueiri, IB Riaz, H Elmarakeby, ... Nature communications 12 (1), 7304, 2021 | 31 | 2021 |
| Body mass index and all‐cause mortality in patients with hypertension W Xu, M Shubina, SI Goldberg, A Turchin Obesity 23 (8), 1712-1720, 2015 | 25 | 2015 |
| Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors E Yekedüz, D Trapani, W Xu, EGE de Vries, C Labaki, B Gyawali, S Gulati, ... International journal of cancer 149 (7), 1455-1462, 2021 | 18 | 2021 |
| A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ... Cancer cell 38 (6), 761-766, 2020 | 18 | 2020 |
| Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma W Xu, M Puligandla, J Manola, AJ Bullock, D Tamasauskas, ... Clinical Cancer Research 25 (20), 6098-6106, 2019 | 14 | 2019 |
| Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805) W Xu, M Puligandla, B Halbert, NB Haas, KT Flaherty, RG Uzzo, ... Clinical Cancer Research 27 (12), 3397-3403, 2021 | 10 | 2021 |
| Time to SARS‐CoV‐2 clearance among patients with cancer and COVID‐19 W Xu, AJ Piper‐Vallillo, P Bindal, J Wischhusen, JM Patel, DB Costa, ... Cancer Medicine 10 (5), 1545-1549, 2021 | 10 | 2021 |
| Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study. L Hirsch, N Martinez Chanza, S Farah, R Flippot, N Rathi, K Collier, ... Journal of clinical oncology 39 (6_suppl), 310-310, 2021 | 9 | 2021 |
Toni ChoueiriDana-Farber Cancer InstituteVerified email at dfci.harvard.edu
